Nicholas Lydon, Director at Blueprint Medicines Corp (BPMC), sold 25,000 shares at $90.36 ($2.3M) on 2019-06-13, disclosed to the SEC on 2019-06-17.
Open-market sale of $2.3M BPMC by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| Filing → |
| BPMC | SELL | 2020-07-08 | $4.1M | — | Filing → |
| BPMC | SELL | 2020-07-06 | $661K | — | Filing → |
| BPMC | SELL | 2020-06-25 | $32K | — | Filing → |